SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Marcel Ukah, Olusegun Badejoko, Solomon Ogunniyi, Olabisi Loto, Oladiipo Aboderin, Adesegun Fatusi, A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in pregnancy, International Journal of Gynecology & Obstetrics, 2015, 131, 1, 41

    CrossRef

  2. 2
    JGC van Hasselt, A Gupta, Z Hussein, JH Beijnen, JHM Schellens, ADR Huitema, Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin, CPT: Pharmacometrics & Systems Pharmacology, 2015, 4, 7
  3. 3
    Xiaoyan Yang, Catherine MT Sherwin, Tian Yu, Venkata K Yellepeddi, Hermine I Brunner, Alexander A Vinks, Pharmacokinetic modeling of therapies for systemic lupus erythematosus, Expert Review of Clinical Pharmacology, 2015, 8, 5, 587

    CrossRef

  4. 4
    P. G. J. ter Horst, J. H. Proost, J. P. Smit, M. T. Vries, L. T. W. de Jong-van de Berg, B. Wilffert, Pharmacokinetics of clomipramine during pregnancy, European Journal of Clinical Pharmacology, 2015, 71, 12, 1493

    CrossRef

  5. 5
    J. G. Coen van Hasselt, Natasha K. A. van Eijkelenburg, Jos H. Beijnen, Jan H.M. Schellens, Alwin D. R. Huitema, Design of a drug-drug interaction study of vincristine with azole antifungals in pediatric cancer patients using clinical trial simulation, Pediatric Blood & Cancer, 2014, 61, 12
  6. 6
    Thury O. Axelsdottir, Emil L. Sigurdsson, Anna M. Gudmundsdottir, Hildur Kristjansdottir, Johann A. Sigurdsson, Drug use during early pregnancy: Cross-sectional analysis from the Childbirth and Health Study in Primary Care in Iceland, Scandinavian Journal of Primary Health Care, 2014, 32, 3, 139

    CrossRef

  7. 7
    Alice Ban Ke, Srikanth C. Nallani, Ping Zhao, Amin Rostami-Hodjegan, Jashvant D. Unadkat, Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19, British Journal of Clinical Pharmacology, 2014, 77, 3
  8. 8
    J. G. C. van Hasselt, K. van Calsteren, L. Heyns, S. Han, M. Mhallem Gziri, J. H. M. Schellens, J. H. Beijnen, A. D. R. Huitema, F. Amant, Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel, Annals of Oncology, 2014, 25, 10, 2059

    CrossRef

  9. 9
    J. G. Coen van Hasselt, Karel Allegaert, Kristel van Calsteren, Jos H. Beijnen, Jan H. M. Schellens, Alwin D. R. Huitema, Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy, BioMed Research International, 2014, 2014, 1

    CrossRef

  10. 10
    Johan G.C. Hasselt, Natasha K.A. Eijkelenburg, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema, Optimizing drug development of anti-cancer drugs in children using modelling and simulation, British Journal of Clinical Pharmacology, 2013, 76, 1
  11. 11
    AA Vinks, The Future of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure in Pregnant Women, CPT: Pharmacometrics & Systems Pharmacology, 2013, 2, 3
  12. 12
    Michael D. Reed, Donald R. Mattison, Clinical Pharmacology During Pregnancy, 2013,

    CrossRef